METASTATIC GASTRIC ADENOCARCINOMA
Clinical trials for METASTATIC GASTRIC ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new METASTATIC GASTRIC ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for METASTATIC GASTRIC ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New way to deliver chemo shows promise for stomach cancer patients
Disease control OngoingThis early-phase study is testing a chemotherapy drug called paclitaxel, given directly into the abdomen, for people with advanced stomach or gastroesophageal cancer that has spread to the lining of the abdomen. The main goal is to find the safest dose and understand side effects…
Matched conditions: METASTATIC GASTRIC ADENOCARCINOMA
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 17, 2026 03:11 UTC
-
Radiation boost may extend life for limited-spread stomach and esophageal cancers
Disease control OngoingThis study tests whether adding radiation therapy to standard chemotherapy helps people with HER2 negative esophageal or stomach cancer that has spread to only a few spots in the body. About 314 participants will receive either chemotherapy alone or chemotherapy plus radiation. T…
Matched conditions: METASTATIC GASTRIC ADENOCARCINOMA
Phase: PHASE3 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Disease control
Last updated May 14, 2026 12:06 UTC
-
Stomach cancer combo fails to shrink tumors in early trial
Disease control OngoingThis study tested a combination of two drugs, berzosertib and irinotecan, in 17 people with advanced stomach or gastroesophageal junction cancer that had a specific genetic change (TP53 mutation) and was no longer responding to other treatments. The goal was to see if the combina…
Matched conditions: METASTATIC GASTRIC ADENOCARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 14, 2026 12:05 UTC
-
Two-Drug combo shows promise in Hard-to-Treat cancers
Disease control OngoingThis early-phase trial tests a combination of two drugs—sonidegib and pembrolizumab—in people with advanced solid tumors that have spread. The goal is to find the safest dose of sonidegib when used with pembrolizumab and to see if the pair can shrink tumors. About 36 adults with …
Matched conditions: METASTATIC GASTRIC ADENOCARCINOMA
Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 08, 2026 12:00 UTC